|
1
|
Skoko D, Wong B, Johnson RC and Marko JF:
Micromechanical analysis of the binding of DNA-bending proteins
HMGB1, NHP6A, and HU reveals their ability to form highly stable
DNA-protein complexes. Biochemistry. 43:13867–13874. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pallier C, Scaffidi P, Chopineau-Proust S,
et al: Association of chromatin proteins high mobility group box
(HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell.
14:3414–3426. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yuan F, Gu L, Guo S, Wang C and Li GM:
Evidence for involvement of HMGB1 protein in human DNA mismatch
repair. J Biol Chem. 279:20935–20940. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Andersson U, Wang H, Palmblad K, et al:
High mobility group 1 protein (HMG-1) stimulates proinflammatory
cytokine synthesis in human monocytes. J Exp Med. 192:565–570.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fiuza C, Bustin M, Talwar S, et al:
Inflammation-promoting activity of HMGB1 on human microvascular
endothelial cells. Blood. 101:2652–2660. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang H, Bloom O, Zhang M, et al: HMG-1 as
a late mediator of endotoxin lethality in mice. Science.
285:248–251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang H, Yang H and Tracey KJ:
Extracellular role of HMGB1 in inflammation and sepsis. J Intern
Med. 255:320–331. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Angus DC, Linde-Zwirble WT, Lidicker J,
Clermont G, Carcillo J and Pinsky MR: Epidemiology of severe sepsis
in the United States: analysis of incidence, outcome, and
associated costs of care. Crit Care Med. 29:1303–1310. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lehr HA, Bittinger F and Kirkpatrick CJ:
Microcirculatory dysfunction in sepsis: a pathogenetic basis for
therapy? J Pathol. 190:373–386. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bae JS and Rezaie AR: Activated protein C
inhibits high mobility group box 1 signaling in endothelial cells.
Blood. 118:3952–3959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mullins GE, Sunden-Cullberg J, Johansson
AS, et al: Activation of human umbilical vein endothelial cells
leads to relocation and release of high-mobility group box
chromosomal protein 1. Scand J Immunol. 60:566–573. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang H, Ochani M, Li J, et al: Reversing
established sepsis with antagonists of endogenous high-mobility
group box 1. Proc Natl Acad Sci USA. 101:296–301. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qin S, Wang H, Yuan R, et al: Role of
HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med.
203:1637–1642. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paul CP, Good PD, Winer I and Engelke DR:
Effective expression of small interfering RNA in human cells. Nat
Biotechnol. 20:505–508. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paddison PJ, Caudy AA, Bernstein E, Hannon
GJ and Conklin DS: Short hairpin RNAs (shRNAs) induce
sequence-specific silencing in mammalian cells. Genes Dev.
16:948–958. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuniyasu H, Chihara Y and Kondo H:
Differential effects between amphoterin and advanced glycation end
products on colon cancer cells. Int J Cancer. 104:722–727. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shapiro NI, Yano K, Sorasaki M, Fischer C,
Shih SC and Aird WC: Skin biopsies demonstrate site-specific
endothelial activation in mouse models of sepsis. J Vasc Res.
46:495–502. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nooteboom A, van der Linden CJ and
Hendriks T: Modulation of adhesion molecule expression on
endothelial cells after induction by lipopolysaccharide-stimulated
whole blood. Scand J Immunol. 59:440–448. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sessler CN, Windsor AC, Schwartz M, et al:
Circulating ICAM-1 is increased in septic shock. Am J Respir Crit
Care Med. 151:1420–1427. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bandyopadhyay S, Ashraf MZ, Daher P, Howe
PH and DiCorleto PE: HOXA9 participates in the transcriptional
activation of E-selectin in endothelial cells. Mol Cell Biol.
27:4207–4216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trivedi CM, Patel RC and Patel CV:
Differential regulation of HOXA9 expression by nuclear factor kappa
B (NF-kappaB) and HOXA9. Gene. 408:187–195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weissberg PL and Bennett MR:
Atherosclerosis - an inflammatory disease. N Engl J Med.
340:1928–1929. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen JW, Chen YH, Lin FY, Chen YL and Lin
SJ: Ginkgo biloba extract inhibits tumor necrosis
factor-alpha-induced reactive oxygen species generation,
transcription factor activation, and cell adhesion molecule
expression in human aortic endothelial cells. Arterioscler Thromb
Vasc Biol. 23:1559–1566. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patel CV, Sharangpani R, Bandyopadhyay S
and DiCorleto PE: Endothelial cells express a novel, tumor necrosis
factor-alpha-regulated variant of HOXA9. J Biol Chem.
274:1415–1422. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ross R: The pathogenesis of
atherosclerosis: a perspective for the 1990s. Nature. 362:801–809.
1993. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tracey KJ, Beutler B, Lowry SF, et al:
Shock and tissue injury induced by recombinant human cachectin.
Science. 234:470–474. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hesse DG, Tracey KJ, Fong Y, et al:
Cytokine appearance in human endotoxemia and primate bacteremia.
Surg Gynecol Obstet. 166:147–153. 1988.PubMed/NCBI
|
|
28
|
Beutler BA, Milsark IW and Cerami A:
Cachectin/tumor necrosis factor: production, distribution, and
metabolic fate in vivo. J Immunol. 135:3972–3977. 1985.PubMed/NCBI
|
|
29
|
Fink MP: Another negative clinical trial
of a new agent for the treatment of sepsis: rethinking the process
of developing adjuvant treatments for serious infections. Crit Care
Med. 23:989–991. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fisher CJ Jr, Dhainaut JF, Opal SM, et al:
Phase III rhIL-1ra Sepsis Syndrome Study Group: Recombinant human
interleukin 1 receptor antagonist in the treatment of patients with
sepsis syndrome. Results from a randomized, double-blind,
placebo-controlled trial. JAMA. 271:1836–1843. 1994. View Article : Google Scholar
|
|
31
|
Eskandari MK, Bolgos G, Miller C, Nguyen
DT, DeForge LE and Remick DG: Anti-tumor necrosis factor antibody
therapy fails to prevent lethality after cecal ligation and
puncture or endotoxemia. J Immunol. 148:2724–2730. 1992.
|
|
32
|
Remick D, Manohar P, Bolgos G, Rodriguez
J, Moldawer L and Wollenberg G: Blockade of tumor necrosis factor
reduces lipopolysaccharide lethality, but not the lethality of
cecal ligation and puncture. Shock. 4:89–95. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luan ZG, Zhang H, Yang PT, Ma XC, Zhang C
and Guo RX: HMGB1 activates nuclear factor-κB signaling by RAGE and
increases the production of TNF-α in human umbilical vein
endothelial cells. Immunobiology. 215:956–962. 2010.
|
|
34
|
Unoshima M: Therapeutic effect of
anti-HMGB1 antibody and anti-RAGE antibody on SIRS/sepsis. Nihon
Rinsho. 62:2323–2329. 2004.(In Japanese).
|
|
35
|
Parrish W and Ulloa L: High-mobility group
box-1 isoforms as potential therapeutic targets in sepsis. Methods
Mol Biol. 361:145–162. 2007.PubMed/NCBI
|
|
36
|
Eriksson M: Should high mobility group
box-1 protein (HMGB1) be measured in patients with severe sepsis
and septic shock? If so, when, where, and how? Crit Care Med.
33:682–683. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ulloa L, Ochani M, Yang H, et al: Ethyl
pyruvate prevents lethality in mice with established lethal sepsis
and systemic inflammation. Proc Natl Acad Sci USA. 99:12351–12356.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo RF and Ward PA: Role of C5a in
inflammatory responses. Annu Rev Immunol. 23:821–852. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mantell LL, Parrish WR and Ulloa L: HMGB-1
as a therapeutic target for infectious and inflammatory disorders.
Shock. 25:4–11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ulloa L and Messmer D: High-mobility group
box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev.
17:189–201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ferrari S, Finelli P, Rocchi M and Bianchi
ME: The active gene that encodes human high mobility group 1
protein (HMG1) contains introns and maps to chromosome 13.
Genomics. 35:367–371. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kornblit B, Munthe-Fog L, Petersen SL,
Madsen HO, Vindelov L and Garred P: The genetic variation of the
human HMGB1 gene. Tissue Antigens. 70:151–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bustin M and Reeves R: High-mobility-group
chromosomal proteins: architectural components that facilitate
chromatin function. Prog Nucleic Acid Res Mol Biol. 54:35–100.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ferrari S, Ronfani L, Calogero S and
Bianchi ME: The mouse gene coding for high mobility group 1 protein
(HMG1). J Biol Chem. 269:28803–28808. 1994.PubMed/NCBI
|
|
45
|
Hardman CH, Broadhurst RW, Raine AR,
Grasser KD, Thomas JO and Laue ED: Structure of the A-domain of
HMG1 and its interaction with DNA as studied by heteronuclear
three- and four-dimensional NMR spectroscopy. Biochemistry.
34:16596–16607. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kuhns DB, Alvord WG and Gallin JI:
Increased circulating cytokines, cytokine antagonists, and
E-selectin after intravenous administration of endotoxin in humans.
J Infect Dis. 171:145–152. 1995. View Article : Google Scholar
|
|
47
|
Boldt J, Muller M, Kuhn D, Linke LC and
Hempelmann G: Circulating adhesion molecules in the critically ill:
a comparison between trauma and sepsis patients. Intensive Care
Med. 22:122–128. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kayal S, Jais JP, Aguini N, Chaudiere J
and Labrousse J: Elevated circulating E-selectin, intercellular
adhesion molecule 1, and von Willebrand factor in patients with
severe infection. Am J Respir Crit Care Med. 157:776–784. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Harlan JM and Winn RK:
Leukocyte-endothelial interactions: clinical trials of
anti-adhesion therapy. Crit Care Med. 30:S214–S219. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Treutiger CJ, Mullins GE, Johansson AS, et
al: High mobility group 1 B-box mediates activation of human
endothelium. J Intern Med. 254:375–385. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zappavigna V, Falciola L, Helmer-Citterich
M, Mavilio F and Bianchi ME: HMG1 interacts with HOX proteins and
enhances their DNA binding and transcriptional activation. EMBO J.
15:4981–4991. 1996.PubMed/NCBI
|
|
52
|
Mark M, Rijli FM and Chambon P: Homeobox
genes in embryogenesis and pathogenesis. Pediatr Res. 42:421–429.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Trivedi CM, Patel RC and Patel CV:
Homeobox gene HOXA9 inhibits nuclear factor-kappa B dependent
activation of endothelium. Atherosclerosis. 195:50–60. 2007.
View Article : Google Scholar : PubMed/NCBI
|
